3-aminomethyl-1-(p-methoxybenzyl)piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-aminomethyl-1-(p-methoxybenzyl)piperidine
• 英文别名: [1-[(4-Methoxyphenyl)methyl]piperidin-3-yl]methanamine
• 化学式: C₁₄H₂₂N₂O
• mdl: MFCD10003339
• 分子量: 234.341
• InChiKey: SBHNECOLJHKHAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-aminomethyl-1-(p-methoxybenzyl)piperidine 、 4-氯苯甲醚 在 copper(l) iodide 、 potassium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 0.33h， 以28%的产率得到4-methoxy-N-((1-(4-methoxybenzyl)piperidin-3-yl)methyl)aniline
  参考文献：
  名称：

  Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors

  摘要：

  In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP I. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.055
• 作为产物：
  描述：

  3-Boc-氨甲基哌啶 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 27.0h， 生成 3-aminomethyl-1-(p-methoxybenzyl)piperidine
  参考文献：
  名称：

  Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors

  摘要：

  In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP I. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.055

文献信息

• Pyrimidine derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05736550A1

  公开（公告）日：1998-04-07

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like; R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group; R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  嘧啶衍生物可用作胃肠促动力药物，其化学式表示为##STR1##其中X为O或NR.sup.5，Y为O、S或NR.sup.5，其中R.sup.5为氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.1和R.sup.2可以相同也可以不同，每个都是氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.3为CN，或COOR.sup.6，其中R.sup.6为C.sub.1 -C.sub.6烷基、C.sub.3 -C.sub.6环烷基、芳基或类似物；R.sup.4为--SR.sup.7或--NR.sup.8 R.sup.9，其中R.sup.7为C.sub.1 -C.sub.6烷基；R.sup.8为C.sub.1 -C.sub.6烷基或类似物；R.sup.9为氢原子、C.sub.1 -C.sub.6烷基或类似物，或R.sup.8和R.sup.9可以与它们连接的氮原子一起表示为化学式(X)的N-取代哌嗪环，其中R.sup.10代表C.sub.1 -C.sub.6烷基或类似物，或其药理学上可接受的盐。上述化合物可用作治疗消化道疾病的胃肠促动力药物。
• NOVEL PYRIMIDINE DERIVATIVE
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0760368A1

  公开（公告）日：1997-03-05

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula (I) wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1-C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1-C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1-C6 alkyl group, a C3-C6 cycloalkyl group, an aryl group or the like; R4 is -SR7 or -NR8R9 wherein R7 is a C1-C6 alkyl group; R8 is a C1-C6 alkyl group or the like; R9 is a hydrogen atom, a C1-C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) wherein R10 represents a C1-C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  可用作胃肠促动力药的嘧啶衍生物，由式（I）表示 其中 X 是 O 或 NR5，Y 是 O、S 或 NR5，其中 R5 是氢原子、C1-C6 烷基或类似物； R1 和 R2 可以相同或不同，各自为氢原子、C1-C6 烷基或类似物； R3 是 CN 或 COOR6，其中 R6 是 C1-C6 烷基、C3-C6 环烷基、芳基或类似基团； R4 是-SR7 或-NR8R9，其中 R7 是 C1-C6 烷基； R8 是 C1-C6 烷基或类似基团； R9是氢原子、C1-C6烷基或类似基团，或R8和R9可与它们所连接的氮原子一起代表式(X)的N-取代的哌嗪环 其中 R10 代表 C1-C6 烷基或类似基团或其药理学上可接受的盐。 上述化合物可用作治疗消化道疾病的胃肠促动力药。
• PYRIMIDINE DERIVATIVES
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0760368B1

  公开（公告）日：1999-07-28
• US5736550A
  申请人：——

  公开号：US5736550A

  公开（公告）日：1998-04-07